In a rapidly changing world, can we truly predict the impact of liver graft quality 15 years from now?
Russell H. Wiesner – 29 June 2015
Reply
John B. Seal, Markus Selzner, George Loss – 29 June 2015
A metabolic chimera: Two defective genotypes make a normal phenotype
Sanjay Govil, Naresh P. Shanmugam, Mettu S. Reddy, Gomathy Narasimhan, Mohamed Rela – 29 June 2015
Reply
Phillip Hylemon, Masayuki Nagahashi, Kazuaki Takabe, Huiping Zhou – 29 June 2015
Prophylaxis of HCV reinfection and direct‐acting antiviral agents during liver transplantation
Marcello Tavio, Marco Vivarelli, Stefano Menzo, Andrea Gori, Paolo Antonio Grossi, Anna Marigliano – 29 June 2015
Negative feedback regulation of bile acid metabolism: Impact on liver metabolism and diseases
John Y.L. Chiang – 29 June 2015
Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection
Jean‐Michel Pawlotsky, Robert Flisiak, Shiv K. Sarin, Jens Rasenack, Teerha Piratvisuth, Wan‐Long Chuang, Cheng‐Yuan Peng, Graham R. Foster, Samir Shah, Heiner Wedemeyer, Christophe Hézode, Wei Zhang, Kelly A. Wong, Bin Li, Claudio Avila, Nikolai V. Naoumov, on behalf of the VITAL‐1 study team – 27 June 2015 – Alisporivir is a cyclophilin inhibitor with pan‐genotypic anti–hepatitis C virus (HCV) activity and a high barrier to viral resistance. The VITAL‐1 study assessed alisporivir as interferon (IFN)‐free therapy in treatment‐naïve patients infected with HCV genotype 2 or 3.
Reply
Peipei Lu, Wen Xie – 25 June 2015
Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus
AASLD/IDSA HCV Guidance Panel – 25 June 2015
Aryl hydrocarbon receptor–fibroblast growth factor 21 dissociation of fatty liver from insulin resistance: A timely matter?
Manlio Vinciguerra, Gianluigi Mazzoccoli – 25 June 2015